Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mel, Spigelman"'
Autor:
Matthias Helble, Tanja Kuchenmüller, John Reeder, Jerome Kim, Bernard Pécoul, David Reddy, Mel Spigelman, Soumya Swaminathan
Publikováno v:
Bulletin of the World Health Organization. 101:355-357
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4980679e6ac46548b94febdf09a2e35
https://doi.org/10.2471/blt.22.289154
https://doi.org/10.2471/blt.22.289154
Autor:
Vishak Subramoney, Jerry R Nedelman, David H Salinger, Mengchun Li, Mel Spigelman, Rob Woolson, Daniel Everitt, Mendel Carl M, Karen Wade
Publikováno v:
Antimicrobial Agents and Chemotherapy
Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intoleran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74dbafb8a3a94dab3539b14888a1535
https://doi.org/10.1128/aac.01121-20
https://doi.org/10.1128/aac.01121-20
Autor:
Mel Spigelman, Richard J. O'Brien
Publikováno v:
Clinics in Chest Medicine. 26:327-340
This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358b5048d86dc91879363f74a6e010bd
https://doi.org/10.1016/j.ccm.2005.02.013
https://doi.org/10.1016/j.ccm.2005.02.013
Autor:
Richard Hafner, Mel Spigelman, Christian Lienhardt, Alimuddin Zumla, Jan Gheuens, Ernesto Jaramillo, Michael Hoelscher, Mario C. Raviglione
For the first time in 40 years, a portfolio of promising new compounds for the treatment of tuberculosis is on the horizon. The introduction of new drugs in combination treatment for all forms of tuberculosis raises several issues related to patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5b865a095c26a6bf3b6cc103352915
http://www.documentation.ird.fr/hor/fdi:010059621
http://www.documentation.ird.fr/hor/fdi:010059621
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 14(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e714d82283985046d387c779b0556e1e
https://pubmed.ncbi.nlm.nih.gov/20487601
https://pubmed.ncbi.nlm.nih.gov/20487601
Publikováno v:
Antimicrobial agents and chemotherapy. 53(9)
The mechanism underlying a dose-dependent, reversible increase in serum creatinine (SC) caused by the administration of PA-824, a novel nitroimidazo-oxazine, was evaluated in 47 healthy male and female volunteers. Subjects were administered either 80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af16d0fcf959a194dc037935603bab6
https://pubmed.ncbi.nlm.nih.gov/19528286
https://pubmed.ncbi.nlm.nih.gov/19528286
Conference
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.